MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad's molecular residual disease assay [Yahoo! Finance]
Myriad Genetics, Inc. (MYGN)
Last myriad genetics, inc. earnings: 2/6 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
myriad.com/news-center/investor-information
Company Research
Source: Yahoo! Finance
HOUSTON and SALT LAKE CITY, Jan. 07, 2025 (GLOBE NEWSWIRE) -- The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad's molecular residual disease (MRD) assay. This strategic alliance brings together the longstanding oncology diagnostic experience of Myriad Genetics and the clinical and translational research expertise of MD Anderson to create a portfolio of studies to evaluate the clinical validity and utility of Myriad's Precise MRD. “We look forward to working with MD Anderson to evaluate Precise MRD's utility in cancer care,” said Dale Muzzey, PhD, Chief Scientific Officer at Myriad Genetics. “Our collabo
Read more
Impact Snapshot
Event Time:
MYGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MYGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MYGN alerts
High impacting Myriad Genetics, Inc. news events
Weekly update
A roundup of the hottest topics
MYGN
News
- Myriad Genetics, Inc. (NASDAQ: MYGN) had its "equal weight" rating re-affirmed by analysts at Stephens. They now have a $20.00 price target on the stock.MarketBeat
- Myriad Genetics expects Q4 revenues to be between $209M and $211M [Seeking Alpha]Seeking Alpha
- Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial GuidanceGlobeNewswire
- Myriad Genetics, Inc. (NASDAQ: MYGN) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer HistoryGlobeNewswire
MYGN
Earnings
- 11/7/24 - Beat
MYGN
Sec Filings
- 1/15/25 - Form 8-K
- 1/2/25 - Form 4
- 12/12/24 - Form 4
- MYGN's page on the SEC website